Full text
Earnings transcript
Read the complete earnings call transcript.
NEOG
Neogen Corporation
$9.41
0.02
(0.21%)
| Exchange: | NASDAQ |
| Market Cap: | 2.047B |
| Shares Outstanding: | 20.615M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Mikhael Nassif | |||||
| Full Time Employees: | 2917 | |||||
| Address: |
| |||||
| Website: | https://www.neogen.com |
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment’s products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 822,447 | 924,222 | 894,661 |
| Gross Profit | 405,955 | 462,635 | 421,376 |
| EBITDA | 122,296 | 182,597 | -937,754 |
| Operating Income | 37,515 | 77,426 | 9,420 |
| Net Income | -22,870 | -9,421 | -1,092,044 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 4,554,432 | 4,548,833 | 3,443,836 |
| Total Liabilities | 1,420,215 | 1,404,691 | 1,372,582 |
| Total Stockholders Equity | 3,134,217 | 3,144,142 | 2,071,254 |
| Total Debt | 900,000 | 906,239 | 894,111 |
| Cash and Cash Equivalents | 163,240 | 170,611 | 129,004 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 41,028 | 35,264 | 58,244 |
| Capital Expenditure | -65,757 | -111,421 | -104,595 |
| Free Cash Flow | -24,729 | -76,157 | 58,244 |
| Net Income | -22,870 | -9,421 | -1,092,044 |
| Net Change in Cash | 118,767 | 7,371 | -41,607 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 827,339.162 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 850,747.557 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 841,000 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -49,171.540 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -47,818.581 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -48,608.151 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 93,418.786 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 96,871.752 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 95,433.739 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 307,931.105 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 316,643.581 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 313,015.594 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.440 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.450 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.430 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Performance: Neogen Corporation reported strong second-quarter revenue for FY 2026, as highlighted in the earnings call transcript, reflecting consistent demand for its products and services within the industry. This aligns with historical revenue data from income statements, indicating a stable growth trajectory.
- Operational Efficiency: The earnings call summary emphasizes improvements in core operations, with a focus on enhancing profitability. Key metrics such as gross profit margin (TTM) and operating income from income statements support a positive trend in cost management and operational effectiveness.
- Strong Balance Sheet Metrics: Balance sheet data shows a healthy level of cash and cash equivalents alongside manageable total liabilities, providing financial flexibility for future investments or debt servicing, as reflected in a reasonable debt-to-equity ratio (TTM).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about NEOG valuation
Is Neogen Corporation (NEOG) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Neogen Corporation (NEOG) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is NEOG a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NEOG trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is NEOG’s P/E ratio?
You can see NEOG’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for NEOG?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is NEOG a good long-term investment?
Whether NEOG fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
NEOG
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.21
Trading Metrics:
| Open: | 9.14 | Previous Close: | 9.39 | |
| Day Low: | 8.93 | Day High: | 9.46 | |
| Year Low: | 3.87 | Year High: | 11.43 | |
| Price Avg 50: | 10.1 | Price Avg 200: | 7.04 | |
| Volume: | 2.129M | Average Volume: | 2.836M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeNEOG full analysis
YouTube Video Transcript: Comprehensive Stock Analysis of Neogen Corporation (NEOG) --- Introduction Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive stock analysis of Neogen Corporation, ticker symbol NEOG, a company that’s been making waves in the healthcare and diagnostics space. Whether you’re a long-term investor or just curious about this stock, I’ve got you covered with everything from financials to recent performance and even an intrinsic value breakdown. So, grab a coffee, hit that…
